101 related articles for article (PubMed ID: 16638701)
1. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C.
Hollander A; Foster GR; Weiland O
Scand J Gastroenterol; 2006 May; 41(5):577-85. PubMed ID: 16638701
[TBL] [Abstract][Full Text] [Related]
2. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin.
Mathew A; Peiffer LP; Rhoades K; McGarrity TJ
Health Qual Life Outcomes; 2006 May; 4():30. PubMed ID: 16696859
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
Arora S; O'Brien C; Zeuzem S; Shiffman ML; Diago M; Tran A; Pockros PJ; Reindollar RW; Gane E; Patel K; Wintfeld N; Green J
J Gastroenterol Hepatol; 2006 Feb; 21(2):406-12. PubMed ID: 16509866
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.
Bonkovsky HL; Snow KK; Malet PF; Back-Madruga C; Fontana RJ; Sterling RK; Kulig CC; Di Bisceglie AM; Morgan TR; Dienstag JL; Ghany MG; Gretch DR;
J Hepatol; 2007 Mar; 46(3):420-31. PubMed ID: 17196293
[TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
6. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.
Bonkovsky HL; Woolley JM
Hepatology; 1999 Jan; 29(1):264-70. PubMed ID: 9862876
[TBL] [Abstract][Full Text] [Related]
7. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
Fujita N; Sugimoto R; Urawa N; Araki J; Mifuji R; Yamamoto M; Horiike S; Tanaka H; Iwasa M; Kobayashi Y; Adachi Y; Kaito M
J Gastroenterol Hepatol; 2007 Nov; 22(11):1886-93. PubMed ID: 17914965
[TBL] [Abstract][Full Text] [Related]
8. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
[TBL] [Abstract][Full Text] [Related]
9. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.
Donnerer J; Grahovac M; Stelzl E; Kessler HH; Bankuti C; Stadlbauer V; Stauber RE
Pharmacology; 2006; 76(3):136-40. PubMed ID: 16410679
[TBL] [Abstract][Full Text] [Related]
10. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
11. The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience.
Pojoga C; Dumitraşcu DL; Pascu O; Grigorescu M
J Gastrointestin Liver Dis; 2006 Mar; 15(1):31-5. PubMed ID: 16680230
[TBL] [Abstract][Full Text] [Related]
12. The comparison of chronic hepatitis C treatment outcome between intravenous drug users and non-intravenous drug users.
Bojovic K; Simonovic J; Katanic N; Milosevic I; Pesic I; Delic D; Svirtlih N; Jevtovic DJ
Biomed Pharmacother; 2013 Jul; 67(6):517-20. PubMed ID: 23639229
[TBL] [Abstract][Full Text] [Related]
13. [Changes in socio-economics, quality of life and knowledge of patients with chronic hepatitis C during the Hepatitis Competence Net Project].
Niederau C; Bemba G; Kautz A
Z Gastroenterol; 2008 Jan; 46(1):22-33. PubMed ID: 18188813
[TBL] [Abstract][Full Text] [Related]
14. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
Moucari R; Ripault MP; Oulès V; Martinot-Peignoux M; Asselah T; Boyer N; El Ray A; Cazals-Hatem D; Vidaud D; Valla D; Bourlière M; Marcellin P
J Hepatol; 2007 Apr; 46(4):596-604. PubMed ID: 17218037
[TBL] [Abstract][Full Text] [Related]
15. Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life.
Nayman Alpat S; Usluer G; Yavuz H; Doyuk Kartal E; Erben N; Bal C; Ozgunes I
J Chemother; 2008 Feb; 20(1):101-5. PubMed ID: 18343751
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
[TBL] [Abstract][Full Text] [Related]
18. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
Nadeem A; Hussain MM; Aslam M; Hussain T; Butt IF; Ali Khan S; Asad A
J Ayub Med Coll Abbottabad; 2009; 21(2):103-6. PubMed ID: 20524482
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt.
Youssef NF; El Kassas M; Farag A; Shepherd A
BMC Gastroenterol; 2017 Jan; 17(1):18. PubMed ID: 28109264
[TBL] [Abstract][Full Text] [Related]
20. Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients.
van Vlerken LG; Huisman EJ; van Soest H; Boland GJ; Drenth JP; Siersema PD; Burger DM; van Erpecum KJ
J Viral Hepat; 2012 Jan; 19(1):39-46. PubMed ID: 21114586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
